| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | D52; N8L; PC-1; PrLZ; hD52 |
| WB Predicted band size | 24 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human TPD52 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于TPD52抗体的3篇代表性文献(内容基于模拟生成，仅供参考)：
---
1. **文献名称**：*TPD52 overexpression in prostate cancer cells promotes proliferation and metastasis through exosome-mediated signaling*
**作者**：Chen, L., et al. (2021)
**摘要**：该研究开发了针对TPD52的特异性单克隆抗体，发现其在前列腺癌细胞中高表达，并通过外泌体传递信号促进肿瘤转移。抗体用于检测临床样本，显示TPD52水平与患者预后负相关。
2. **文献名称**：*Development of a novel monoclonal antibody against TPD52 for immunohistochemical diagnosis in breast cancer*
**作者**：Wang, Y., et al. (2019)
**摘要**：团队成功制备了高灵敏度的抗TPD52单克隆抗体，验证了其在乳腺癌组织中的特异性染色能力，证实TPD52过表达与HER2阳性亚型和化疗耐药性相关。
3. **文献名称**：*TPD52 regulates autophagosome-lysosome fusion via binding to LC3 and its implications in colorectal cancer progression*
**作者**：Kim, S., et al. (2020)
**摘要**：利用TPD52抗体进行免疫共沉淀实验，揭示了TPD52通过结合自噬标记蛋白LC3调控溶酶体融合的功能，其表达缺失导致结直肠癌细胞自噬受阻并增强凋亡。
---
**注**：若需真实文献，建议通过PubMed或Google Scholar以“TPD52 antibody”或“TPD52 biomarker”为关键词检索近年研究。
The tumor protein D52 (TPD52) is a member of the D52-like protein family, initially identified through its overexpression in breast cancer. Encoded by the *TPD52* gene on human chromosome 8q21. this small, coiled-coil motif-containing protein regulates diverse cellular processes, including cell proliferation, apoptosis, vesicular trafficking, and lipid metabolism. TPD52 interacts with signaling pathways like PI3K/AKT and MAPK, and its dysregulation is implicated in cancer progression, metastasis, and therapeutic resistance. Elevated TPD52 expression has been observed in multiple cancers, such as prostate, ovarian, and colorectal cancers, correlating with poor prognosis.
TPD52 antibodies are immunological tools designed to detect and quantify TPD52 protein levels in research and diagnostic contexts. Polyclonal and monoclonal variants are used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study TPD52's spatial expression, post-translational modifications, and interactions in cellular or tissue samples. These antibodies aid in exploring TPD52's role as a potential oncogenic driver or biomarker. Recent studies also investigate its utility in liquid biopsies for cancer monitoring. Commercially available TPD52 antibodies vary in specificity, with validation often performed using knockout cell lines or siRNA-mediated knockdown. Ongoing research focuses on leveraging TPD52-targeting antibodies for therapeutic applications, including antibody-drug conjugates or blocking tumor-stroma crosstalk.
×
